OncoMatch/Clinical Trials/NCT05914545

A Study of FZ-AD004 in Patients With Advanced Solid Tumors

Is NCT05914545 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies FZ-AD004 for advanced and metastatic solid tumor.

Phase 1RecruitingShanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT05914545Data as of Jun 2026Location: China

Treatment: FZ-AD004 — This study is one single group of participants with advanced solid tumors. It is the first time the drug has been used in humans. There will be two parts including Dose Escalation and Dose Expansion to evaluate the safety, tolerability, pharmacokinetics, and clinical activity of FZ-AD004.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

FZ-AD004

Cancer type

Tumor Agnostic

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 75

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT05914545 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 75 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify